SCHEMBL3538869

SCHEMBL3538869

COc1cccnc1Oc1ccc2[nH]nc(-c3nc4ccc(N5CCN(C)CC5)cc4[nH]3)c2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 6/20 0.63
FGFR1 P11362 12/20 0.62
FLT1 P17948 3/20 0.62
KDR P35968 2/20 0.58
PDGFRA P16234 1/20 0.58
FGFR2 P21802 1/20 0.58
FGFR4 P22455 1/20 0.58
FGFR3 P22607 1/20 0.58
CDK4 P11802 1/20 0.56
CCNA2 P20248 1/20 0.56
CCND1 P24385 1/20 0.56
CDK2 P24941 1/20 0.56
CCND3 P30281 1/20 0.56
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
BLM P54132 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534937 0.94 FGFR1 (0.61) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3541239 0.90 ABL1 (0.76) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3536993 0.88 FGFR1 (0.61) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3534388 0.87 FGFR1 (0.60) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3531965 0.87 ABL1 (0.84) ABL1FGFR1FLT1KDRBCR
SCHEMBL3536656 0.87 FGFR1 (0.59) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3536163 0.87 FGFR1 (0.66) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3536287 0.86 ABL1 (0.74) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3536818 0.86 FGFR1 (0.65) ABL1FGFR1FLT1KDRPDGFRA
SCHEMBL3540001 0.86 ABL1 (0.75) ABL1FGFR1FLT1KDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK ABL1 1/4885FGFR1 886/4885FLT1 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.